https://www.selleckchem.com/pr....oducts/mps1-in-6-com
02, hazard ratio [HR] = 0.46, n=100, log-rank test). In a cohort examined after 2005, patients carrying low-ROS CYBA alleles showed 20years longer time to secondary progression (p=0.003, HR = 0.29, n=59, log-rank test). These results implicate NOX2 in MS, in particular for the development of secondary progressive disease, and point toward NOX2-reductive therapy aiming to delay secondary progression. These results implicate NOX2 in MS, in particular for the development of secondary progressive disease, and point toward
Like
Comment
Share
